Marg McGee
Major grant funding to progress lipid-based ...
Major grant funding to progress lipid-based therapies to treat prostate cancer
Marg McGee
Inaugural FCMHW Early Career Research Fellow at ...
Inaugural FCMHW Early Career Research Fellow at Flinders University - Jasmine Petersen
Marg McGee
Congratulations 2022 Honours Scholarship ...

Congratulations to the Centre’s 2022 Honours students on their scholarship awards and we wish them all the best for their research and training

Congratulations 2022 Honours Scholarship awardees
Publications, media release, Feature publication
Kelsey Long
Validation of a short form Male Depression Risk ...

Validation of the Male Depression Risk Scale short form in a cross-sectional study of Australian men. Herreen D, Rice S, Zajac I. Brief assessment of male depression in clinical care:BMJ Open. 2022 Mar 28;12(3):e053650. doi: 10.1136/bmjopen-2021-053650.

Contact: Dr Ian Zajac

Validation of a short form Male Depression Risk Scale
Kelsey Long
The Women of the FCMHW - International Women's ...

To celebrate International Women’s Day, the Centre is highlighting some of the fantastic women of men’s health that have been supported by the Centre and are achieving great work in the field. FCMHW encourages and commends the involvement of women in men’s health and hopes to further support it in the future.

The Women of the FCMHW - International Women's Day

saprostatecancer

Fatty acid oxidation inhibition to treat advanced prostate cancer

Fatty acid oxidation inhibition to treat advanced prostate cancer

With progressed prostate cancer, men are no longer responding to the standard anti-androgen drug therapy. While developing new drugs often can take 15 years, this program will reduce this timeframe by aiming to re-purpose existing lipid-modifying medicines. We aim to take our laboratory findings into a proof-of-concept clinical trial to test whether trimetazidine is safe and effective in treating men on ADT, to prevent or delay the onset of lethal castrate resistant prostate cancer.

Through this trial we aim for a potential new therapeutic approach using existing drugs used to treat cardio-metabolic disease to prevent lethal prostate cancer, reduced drug-related toxicities in men being treated for prostate cancer, and Improved length and quality of life for men living with advanced prostate cancer.

Contact: Dr Zeyad Nassar

Improving precision medicine for men being treated for prostate cancer

Improving precision medicine for men being treated for prostate cancer

The aim of this project is to determine the impact of commonly prescribed classes of concomitant non-cancer medicines (i.e.antibiotics, proton pump inhibitors, lipid- and blood glucose-lowering medications) on the efficacy of treatments for metastatic prostate cancer. To achieve this, we will exploit large clinical trial datasets, sophisticated data analytic methods (e.g. machine learning) and biologically-informed models.

Contact: Dr Ashley Hopkins

Investigating the effects of androgen therapies on the prostate immune system

Investigating the effects of androgen therapies on the prostate immune system

Immunotherapy approaches for prostate cancer have been largely unsuccessful, despite many clinical trials. We propose that harnessing the immune system to treat prostate cancer first requires a better understanding of the unique biology of this disease. The objective of this research program is to investigate the interplay between androgen receptor signalling and immunity in prostate cancer

Contact: A/Prof Luke Selth